EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K / AKT Pathway

Zijian Liu, Jingsheng Yuan, Fei Liu, Qiwen Zeng, Zhenru Wu, Jian Yang iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Zijian Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Liquid Biopsy and Single Cell Research, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postdoctoral Research Foundation of China, Sichuan University Postdoctoral Fund, National Natural Science Foundation of China for Young Scientists Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DEAD‐box RNA helicase (DDX) family is one of the canonical splicing regulators, engaged in RNA metabolism, and generally participates in forming spliceosomes. However, systematic analysis of DDX family members in hepatocellular carcinoma (HCC) has not been conducted before, and their biological functions need to be investigated further. Based on biological function enrichment analysis, radiosensitivity index (RSI), and prediction IC50 index for sorafenib, we ultimately ascertain DDX42 as a candidate gene. DDX42 was highly expressed in HCC than in para‐tumour tissues and was a prognostic factor for HCC patients. Importantly, DDX42 overexpression promotes cell proliferation, radio‐resistance and sorafenib resistance in HCC cells and activates the PI3K/AKT pathway. Knockdown of DDX42 moderately inhibited cell growth of HCC cells and significantly increased radio‐sensitivity, enhanced the efficacy of sorafenib, and inactivated the PI3K/AKT pathway. Mechanically, DDX42 could urge the mRNA maturation of GRB2, contributing to cell proliferation and enhancement of resistance ability to radiotherapy and sorafenib for HCC cells. Subcutaneous xenograft nude mouse model showed that DDX42 significantly promoted tumour growth as compared to the control group and lifted the expression of GRB2, KI‐67 and PCNA in vivo. In conclusion, our findings facilitate the acknowledgment of tumour initiation and mechanisms of treatment resistance in HCC, and targeting the axis of DDX42 and GRB2 may be promising strategies for synergy with radiotherapy or sorafenib for HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularSorafenibLiver NeoplasmsProto-Oncogene Proteins c-aktDEAD-box RNA HelicasesPhosphatidylinositol 3-KinasesDrug Resistance, NeoplasmGRB2 Adaptor ProteinRadiation ToleranceHumansCell ProliferationAnimalsSignal TransductionMiceCell Line, TumorGene Expression Regulation, NeoplasticMice, NudeMaleXenograft Model Antitumor AssaysFemale

Stichwörter der Autor:innen

RNA maturationcell proliferationhepatocellular carcinomaradio‐resistancesorafenib resistance

Substanzen

SorafenibProto-Oncogene Proteins c-aktDEAD-box RNA HelicasesPhosphatidylinositol 3-KinasesGRB2 Adaptor ProteinGRB2 protein, human

Autor:innen und Institutionen

  • Laboratory of Liquid Biopsy and Single Cell Research, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Liver Transplant Center, Transplant Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • Division of Biliary Tract Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Jian Yang

Förderung

  • Postdoctoral Research Foundation of China
  • Sichuan University Postdoctoral Fund
  • National Natural Science Foundation of China for Young Scientists Fund
  • Sichuan Province Science and Technology Department Project
  • Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation
  • Postdoctor Research Fund of West China Hospital, Sichuan University

Zitieren

APA

Liu, Z., Yuan, J., Liu, F., Zeng, Q., Wu, Z., & Yang, J. (2025). DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K / AKT Pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70793

Vancouver

Liu Z, Yuan J, Liu F, Zeng Q, Wu Z, Yang J. DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K / AKT Pathway. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70793

BibTeX
@article{Liu2025,
  author = {Liu, Zijian and Yuan, Jingsheng and Liu, Fei and Zeng, Qiwen and Wu, Zhenru and Yang, Jian},
  title = {DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K / AKT Pathway},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70793}
}
Kostenlos starten →